Vaderis Therapeutics announces oversubscribed $152 million Series B financing

Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare vascular diseases, announced the closing of a private $152 million Series B financing and initiation of HEROIC, the company’s global Phase 3 clinical study evaluating engasertib (VAD044...